Hb level improvements from baseline were nominally significant versus placebo at 12-wk intervals assessed up to wk 96 (Figure).
← all excerpts
S273: LONG-TERM ERYTHROID RESPONSE DATA FROM PATIENTS (PTS) WITH NON-TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA (NTDT) RECEIVING LUSPATERCEPT IN THE BEYOND TRIAL
1
—
—